#RB042 #ClinicalTrial #FirstInHuman #COPD #SSOtherapeutics #SSO #Oligonucleotides #RestoreTheBalance To view or add a comment, sign in Clinical update: Our lead program, RB042, is an inhaled oligonucleotide designed to reduce the amount of the inflammatory isoform (mRAGE) and promoting the anti-inflammatory form (esRAGE)
While copper peptides aren't typically comedogenic, the increased cellular turnover at high concentrations can sometimes trigger acne in susceptible individuals
Glycine Soja (Soybean) Oil, Sorbeth-30 Tetraoleate, Mentha Arvensis Leaf Oil, Melaleuca Alternifolia (Tea Tree) Leaf Oil, Tocopheryl Acetate, Helianthus Annuus (Sunflower) Seed Oil, Olea Europaea (Olive) Fruit Oil, Simmondsia Chinensis (Jojoba) Seed Oil, Oenothera Biennis (Evening Primrose) Oil, Glutathione (100ppm), Niacinamide, Water, Limonene, Glycerin, Dipropylene Glycol, 1,2-Hexanediol, Butylene Glycol, Squalane, Asiaticoside, Madecassic Acid, Asiatic Acid, Hippophae Rhamnoides Fruit Extract, Hydrolyzed Collagen, Beta-Glucan, Artemisia Annua Extract, Oryza Sativa (Rice) Extract, Nelumbo Nucifera Extract, Saccharomyces Ferment, Solanum Melongena (Eggplant) Fruit Extract, Melaleuca Alternifolia (Tea Tree) Leaf Extract *For the most recent ingredient list, please consult the product packaging or contact us for a product photo.
Intracellular glutathione in lymphocytes showed no measurable increase
One trial found that both pregabalin and duloxetine improved patient-reported CIPN symptoms, with 150 mg of pregabalin performing better than 60 mg of duloxetine (Salehifar 2020)
.webp)
